JNJ-64007957 is a bispecific antibody that targets CD3, which is expressed on T-cells and BCMA, which is expressed in mature B lymphocytes. JNJ-64007957 was created under a collaboration between Genmab and Janssen using Genmab's DuoBody technology. JNJ-64007957 is being investigated in a Phase I clinical study to treat relapsed or refractory multiple myeloma.

Back to top

Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells.1  While some patients with multiple myeloma have no symptoms at all, others are diagnosed due to symptoms which can include bone problems, low blood counts, calcium elevation, nervous system symptoms, kidney problems or infections.2 The 5-year survival rate for multiple myeloma patients is estimated at 49.6% in the U.S.3 In 2017, it was expected that approximately 30,280 people would be newly diagnosed with multiple myeloma and approximately 12,590 people would die from the disease in the U.S. in 2015.4  In 2015, it was estimated that approximately 124,225 people worldwide would be diagnosed with multiple myeloma and 87,084 would die from the disease.5

JNJ-64007957 is being investigated in a Phase I study in relapsed or refractory multiple myeloma. For more information, visit

1 American Cancer Society. "Multiple Myeloma Overview." Available
at Accessed August 2015.
2  American Cancer Society. "Signs and Symptoms of Multiple Myeloma." Accessed August 2018.
3  Surveillance, Epidemiology and End Results Program (SEER). SEER Stat Fact Sheets: Myeloma. Available at html/mulmy.html. Accessed December 2017.  
4American Cancer Society. Cancer Statistics Center. BmVYeqHT. Accessed December 2017.
5 GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide: Number of New Cancers in 2015. Available at: Execute. Accessed December 2017. 


Back to top